4.92
Schlusskurs vom Vortag:
$4.98
Offen:
$4.99
24-Stunden-Volumen:
33,615
Relative Volume:
0.16
Marktkapitalisierung:
$11.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.52M
KGV:
-2.3541
EPS:
-2.09
Netto-Cashflow:
$-45.03M
1W Leistung:
+3.36%
1M Leistung:
+946.81%
6M Leistung:
+517.70%
1J Leistung:
+201.84%
Nextcure Inc Stock (NXTC) Company Profile
Firmenname
Nextcure Inc
Sektor
Branche
Telefon
240-399-4900
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Vergleichen Sie NXTC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NXTC
Nextcure Inc
|
4.92 | 11.13M | 0 | -58.52M | -45.03M | -2.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-11-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
2021-03-05 | Hochstufung | Truist | Hold → Buy |
2021-01-15 | Herabstufung | BofA Securities | Neutral → Underperform |
2020-07-16 | Hochstufung | The Benchmark Company | Hold → Buy |
2020-07-13 | Herabstufung | ROTH Capital | Buy → Neutral |
2020-07-13 | Herabstufung | SunTrust | Buy → Hold |
2020-06-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
2020-06-01 | Herabstufung | The Benchmark Company | Buy → Hold |
2020-05-26 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-03-24 | Eingeleitet | The Benchmark Company | Buy |
2020-03-02 | Eingeleitet | ROTH Capital | Buy |
2020-01-13 | Eingeleitet | SunTrust | Buy |
2019-12-05 | Eingeleitet | Needham | Buy |
2019-11-26 | Eingeleitet | BTIG Research | Buy |
2019-07-09 | Eingeleitet | BofA/Merrill | Buy |
2019-06-03 | Eingeleitet | Morgan Stanley | Overweight |
2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
What analysts say about NextCure Inc. stockTriple-digit wealth increases - Autocar Professional
NextCure Inc. Stock Analysis and ForecastMarket-beating returns - Autocar Professional
What drives NextCure Inc. stock priceExceptional return forecasts - jammulinksnews.com
Is NextCure Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
What makes NextCure Inc. stock price move sharplyConsistent Growth Alert - Newser
Why NextCure Inc. stock attracts strong analyst attentionFree Access to Community - Newser
How NextCure Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Piper Sandler lowers NextCure stock price target to $15 after reverse split By Investing.com - Investing.com South Africa
Piper Sandler lowers NextCure stock price target to $15 after reverse split - Investing.com India
NextCure initiates one-for-twelve reverse stock split on Nasdaq By Investing.com - Investing.com Nigeria
NextCure Implements Reverse Stock Split on Nasdaq - TipRanks
NextCure initiates one-for-twelve reverse stock split on Nasdaq - Investing.com
NextCure Announces One-for-Twelve Reverse Stock Split - TipRanks
NextCure announces 1-for-12 reverse stock split effective July 14 - Investing.com Nigeria
NextCure announces 1-for-12 reverse stock split effective July 14 By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
NextCure’s (NXTC) Buy Rating Reaffirmed at HC Wainwright - Defense World
Eyes on Asia: AstraZeneca, NextCure, Sagimet Biosciences - BioXconomy
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX
Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX
NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter
NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Home
NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable
NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener
Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com
NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks
NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus
NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia
Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com
Finanzdaten der Nextcure Inc-Aktie (NXTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):